Roche (RHHBY.US) plans to include MASH new drug in breakthrough therapy.

According to the Wise Finance APP, on May 25th, the CDE website showed that Roche's Pegozafermin is planned to be included in a breakthrough therapy for the treatment of metabolic dysfunction-associated fatty liver disease (MASH).